Glax­o­SmithK­line cell ther­a­py lead leaves for part­ner; Fer­ring and Igenomix cre­ate Boston hub for ma­ter­nal health

→ Glax­o­SmithK­line is los­ing its cell ther­a­py R&D chief to a part­ner. Im­mat­ics hired Cedrik Brit­ten, who had been head of GSK’s on­col­o­gy cell ther­a­py re­search unit, as CMO. In Feb­ru­ary, GSK struck an up-to $600 mil­lion deal with Im­mat­ics ($50 mil­lion up­front) to use their bi-spe­cif­ic T-cell re­cep­tor plat­form. Im­mat­ics’ cur­rent CMO Carsten Rein­hardt will be­come chief de­vel­op­ment of­fi­cer.

→ Switzer­land-based Fer­ring and Spain’s Igenomix have signed a ma­ter­nal health and re­pro­duc­tive med­i­cine re­search pact. The pact will see the two com­pa­nies cre­ate a re­search hub in Boston in an ef­fort to dis­cov­er new tar­gets and dis­ease mech­a­nisms for in­fer­til­i­ty and oth­er preg­nan­cy-re­lat­ed con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER